Efficacia e tollerabilità del Seaprose S in pazienti con mastalgia di origine benigna

Citato 2 volte in letteratura internazionale (Fonte: Scopus.com) This open study assessed the anti-inflammatory activity of Seaprose S in patients with benign mastopathy. Thirty women, a mean age 28.9 ± 6.8 years (SD) were treated with Seaprose S per os (30 mg 3 tabs/day) for 14 days. The results show the constant therapeutic action of Seaprose S which controlled the mammary symptoms (pain, pain under pressure, tension) in over 80% of the patients. The drug's therapeutic safety profile is also noteworthy since there were no undesired effects at all during the study. The absence of side effects and the considerable anti-inflammatory activity of Seaprose S observed in this study illustrate its efficacy in controlling and reducing inflammatory pain in women with benign mastopathy.